You are here
The future of non-dopaminergic treatments - part 2 of 2
Professor Shitij Kapur
Prof. Shitij Kapur gives a retrospective overview of antipsychotics in clinical phases 1, 2 and 3. Half of these drugs in phase 2 and 3 are variants of current D2 blocking antipsychotics. Within the other group that were not D2 blocking antipsychotics, he identifies three main streams of drug development: drugs working on the glutamate system, drugs working on the phosphodiesterase 10 (PDE10) enzyme, and those working on the alpha-7 (α7) nicotinic receptor. He reflects on the challenges and current limitations of these research pathways, but remains positive about future advances that these channels could provide, especially in the field of cognition.